1.39 USD
▲+0.03+2.96%
盘后 1.35 -0.24%
2026-08-03
市值
$5.78M
市盈率
—
EPS
-12.38
股息率
—
52 周区间
1.21 – 10.00
成交量
11.39K
Beta
2.24
目标价
—
52W 低 1.2152W 高 10.00
价格走势
公司简介
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study...